REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 30449 participants.

Also called NCT01252953

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 30,449 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01252953
  • EudraCT 2010-023467-18
Main results
  • Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease The New England journal of medicine, 2017-09-28 DOI, PubMed 28847206
Other papers using this trial's data
  • Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States Journal of the American Heart Association, 2023-10-03 DOI, PubMed 37750555, PMC7615160 In the PMC Open Access subset under CC BY.
  • Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease European heart journal, 2022-04-06 DOI, PubMed 34910136, PMC8986460 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT01252953. Randomized; quadruple masking; primary purpose prevention. Start 2011-06 (registry gives no type); primary completion 2017-01-31 (actual). Results posted on 2018-05-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Acronym
REVEAL
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Anacetrapib
Intervention (Drug)
Placebo anacetrapib
Lead sponsor
University of Oxford (class: other)
Collaborator
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01252953
Content hash
d5b6eede96b7c5ace3409700417f10939e0cd823b06e7367c167ca7da21407f1